You can get prescribed Humatin® through LifeMD. LifeMD can connect you with a medical provider who will write you a prescription for Humatin® if appropriate.
Stop your intestinal parasite in its tracks. Humatin is a prescription medication used to treat acute and chronic intestinal amebiasis and the management of hepatic coma as an adjunctive therapy.
Humatin® has been used for decades to treat parasitic infections including amebiasis, giardiasis, leishmaniasis, and tapeworm infection.
Humatin’s effectiveness speaks for itself, it’s on the World Health Organization’s List of Essential Medicines.
Humatin has partnered with LifeMD, a telehealth company that connects you with doctors who can write prescriptions online.
Limited Time Offer: Save 50% on your prescription consultation.
We’ve taken the complication and time out of healthcare.
LifeMD makes it easy to gain access to the medications you need. Getting help is fast, simple, and affordable.
Step 1
Report your symptoms and medical history for evaluation and diagnosis by a board-certified provider.
Step 2
If appropriate, your doctor will write a prescription for Humatin. In most cases, patients receive their prescription the same day.
Step 3
Get your medication delivered and start using Humatin to treat your parasitic infection.
Limited Time Offer: Save 50% on your prescription consultation.
Clinically proven results.
Humatin® has been used for decades to treat a number of parasitic infections including amebiasis, giardiasis, leishmaniasis, and tapeworm infection.
For over 50 years, Humatin® has been used to treat parasitic infections.
Humatin is an FDA-approved medication, which means it passed rigorous safety and efficacy testing in clinical trials.
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Humatin® for a condition for which it was not prescribed. Do not give Humatin® to other people, even if they have the same problem you have. It may harm them.
Telehealth is dramatically changing the way we think about and access healthcare. Now you can skip waiting for physical appointments for treatment, while saving time and money all along the way. Start treatment by booking your appointment today, it’ll take less than 2 minutes!
Book your appointmentParomomycin is an antimicrobial used to treat a number of parasitic infections including amebiasis, giardiasis, leishmaniasis, and tapeworm infection.
Amebiasis, also known as amoebiasis or amoebic dysentery,is a parasite called Entamoeba histolytica, or E. histolytica. This infection is caused by ingesting entamoeba histolytica cysts found in water, soil, or fertilizer contaminated with feces. The symptoms range from diarrhea, stomach pain, and stomach cramping to more severe effects of amebic dysentery, including bloody stool, fever, and severe stomach pain.
When cysts enter the human body, they release a parasite called trophozoite in the digestive tract, which reproduces in the large intestinal wall or colon, causing bloody stool, colitis, and stomach pain.
Anyone can become infected; however, it is most common in
When a person becomes infected, the parasite can spread to others through stool, even if the infected person doesn’t have symptoms. Individuals can also become infected if they touch a contaminated surface and bring their hands to their mouth.
While anyone can contract this parasitic infection, it is most common in places with poor sanitary conditions. If you are traveling to a country with poor sanitary conditions, take the proper precautions to avoid contracting amebiasis:
Your doctor will confirm via stool sample if you have Amebiasis, and may prescribe an anti-parasitic medication like Humatin™ to treat it.
Start treating your symptoms with Humatin®
by booking a doctor consultation with LifeMD. Save 50% off your consultation today,
just pay $24.50!
About HUMATIN™: Paromomycin Sulfate Capsules?
HUMATIN™ is a prescription medicine, also known as an aminoglycoside antibiotic, containing paromomycin sulfate to treat acute and chronic intestinal amebiasis and the management of hepatic coma as an adjunctive therapy. It is not effective in extraintestinal amebiasis.
Amebiasis is a disease caused by a parasite called Entamoeba Histolytica that infects the intestines. When this occurs, individuals could experience symptoms, including diarrhea, bloody stool, stomach pain, cramping, fever, loss of appetite, and nausea. To stop the growth of the intestinal parasite, your doctor can prescribe HUMATIN™. Because the medication is poorly absorbed into the bloodstream, it only treats intestinal parasitic infections, not extraintestinal infections.
Your doctor may also prescribe HUMATIN™ to treat hepatic coma, also known as hepatic encephalopathy, a nervous system disorder caused by liver disease, as an adjunctive therapy. These individuals have intestinal bacteria that produce too much ammonia in the liver, and HUMATIN™ can help stop bacterial growth.
Note: While taking HUMATIN™, it’s important to have your doctor monitor you for the overgrowth of other organisms, such as fungi.
INDICATIONS AND USAGE
Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
CONTRAINDICATIONS
Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.
PRECAUTIONS
Prescribing HUMATIN™ Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.
Information for Patients
Patients should be counseled that antibacterial drugs including HUMATIN™ Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When HUMATIN™ Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by HUMATIN™ Capsules or other antibacterial drugs in the future.
PEDIATRIC USE
See DOSAGE AND ADMINISTRATION.
DOSAGE AND ADMINISTRATION
HOW SUPPLIED
HUMATIN™ Capsules each contain paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows:
NDC 80725-250-01: Bottles of 100
The capsule is Dark Blue Opaque /White Opaque, imprinted with “HP 38” in black ink on the cap and on the body.
ADVERSE REACTIONS
Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily.
To report SUSPECTED ADVERSE REACTIONS, Waylis Therapeutics LLC at 844-200-7910 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
INDICATIONS AND USAGE
Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
CONTRAINDICATIONS
Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.
PRECAUTIONS
Prescribing HUMATIN™ Capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.
Information for Patients
Patients should be counseled that antibacterial drugs including HUMATIN™ Capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When HUMATIN™ Capsules is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by HUMATIN™ Capsules or other antibacterial drugs in the future.
See DOSAGE AND ADMINISTRATION.
DOSAGE AND ADMINISTRATION
HOW SUPPLIED
HUMATIN™ Capsules each contain paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows:
NDC 80725-250-01: Bottles of 100
The capsule is Dark Blue Opaque /White Opaque, imprinted with “HP 38” in black ink on the cap and on the body.
ADVERSE REACTIONS
Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily.
To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
